Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications
Role of molecular driver mutations in recurrence of early-stage laryngeal cancer following narrow field definitive radiotherapy.
Journal: Oral oncology reports
Published: May 13, 2026
Corrigendum to "Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice" [Eur. J. Cancer 238 (May) (2026) 116686].
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 01, 2026
Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 27, 2026
Delta-Like Ligand 3 Expression by Immunohistochemistry in Rare Neuroendocrine Neoplasms and Associated Response to Off-Label Tarlatamab Treatment.
Journal: JCO precision oncology
Published: January 23, 2026
Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 12, 2026
Response to letter Re: Tarlatamab-induced immune-related adverse events: Real-world pharmacovigilance study using the FAERS database.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 13, 2025
Outcomes of Concurrent Radiotherapy With Tarlatamab in Extensive-Stage Small Cell Lung Cancer From the DLL3 PanTUMOR Database.
Journal: Clinical lung cancer
Published: September 23, 2025
Tarlatamab-induced immune-related adverse events: Real-world pharmacovigilance study using the FAERS database.
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 13, 2025
Safety, Efficacy, and Central Nervous System Control in Patients with High Baseline Risk Factors Treated with Tarlatamab for SCLC or Extrapulmonary Small Cell Carcinoma.
Journal: JTO clinical and research reports
Published: March 10, 2025
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 16, 2024
Comparison of the effectiveness of oral morphine versus oral tramadol on early pain control in opioid-naive patients with moderate cancer pain.
Journal: Ecancermedicalscience
Published: November 16, 2024
Tarlatamab Rechallenge After Grade 3 Cytokine Release Syndrome Leading to Tumor Regression in Two Weeks and Reopening of a Collapsed Lung: A Case Report.
Journal: Clinical lung cancer
Published: October 11, 2024
Last Updated: 09/26/2026